[Diagnosis and therapy for attention-getting infections (discussion)].
Koike
Kazuhiko
K
Oka
Shinichi
S
Kaku
Mitsuo
M
Mizokami
Masashi
M
Harada
Sohei
S
D023241:Antiretroviral Therapy, Highly Active / Q000639:trends; D000998:Antiviral Agents / Q000627:therapeutic use; D002423:Cause of Death; D003428:Cross Infection / Q000382:microbiology / Q000821:virology; D004196:Disease Outbreaks; D024901:Drug Resistance, Multiple, Bacterial; D024882:Drug Resistance, Viral; D014943:Global Health; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology; D006509:Hepatitis B / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D007564:Japan / Q000453:epidemiology; D019259:Lamivudine / Q000627:therapeutic use; D008457:Measles / Q000453:epidemiology; D017410:Practice Guidelines as Topic; D011552:Pseudomonas Infections / Q000453:epidemiology / Q000382:microbiology; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D014765:Viral Vaccines
D000998:Antiviral Agents; D018894:Reverse Transcriptase Inhibitors; D014765:Viral Vaccines; D019259:Lamivudine